CA2032475A1 - Preparations pharmaceutiques pour administration par voie orale permettant la liberation du medicament dans des endroits cibles de l'intestin - Google Patents

Preparations pharmaceutiques pour administration par voie orale permettant la liberation du medicament dans des endroits cibles de l'intestin

Info

Publication number
CA2032475A1
CA2032475A1 CA2032475A CA2032475A CA2032475A1 CA 2032475 A1 CA2032475 A1 CA 2032475A1 CA 2032475 A CA2032475 A CA 2032475A CA 2032475 A CA2032475 A CA 2032475A CA 2032475 A1 CA2032475 A1 CA 2032475A1
Authority
CA
Canada
Prior art keywords
intestines
ingredient
layer
release
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2032475A
Other languages
English (en)
Other versions
CA2032475C (fr
Inventor
Heiji Ikushima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2032475A1 publication Critical patent/CA2032475A1/fr
Application granted granted Critical
Publication of CA2032475C publication Critical patent/CA2032475C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Préparation pharmaceutique améliorée pour administration orale, adaptée pour libérer le médicament dans des sites particuliers de l'intestin. La préparation comprend un noyau contenant un ingrédient actif et un excipient de qualité pharmaceutique acceptable; une première couche recouvrant ce noyau, composée d'un ingrédient kératinisé ou hydrosoluble et un ingrédient facultatif insoluble; une seconde couche recouvrant la première, composée d'un ingrédient non kératinisé qui se dissout en réagissant avec au moins un ingrédient contenu dans le noyau; et une troisième couche recouvrant la seconde, composée d'un ingrédient kératinisé. Cette préparation se caractérise, d'une part, en ce qu'elle ne libère pas l'ingrédient actif tant qu'elle n'a pas atteint un site choisi dans l'intestin et, d'autre part, en ce qu'elle peut contrôler la vitesse à laquelle l'ingrédient actif est libéré après avoir atteint le site choisi. Elle est donc particulièrement efficace pour administrer des ingrédients actifs ayant une spécificité d'absorption à des sites particuliers de l'intestin ou pour traiter des maladies situées dans des sites particuliers de l'intestin.
CA002032475A 1989-05-11 1990-05-10 Preparations pharmaceutiques pour administration par voie orale permettant la liberation du medicament dans des endroits cibles de l'intestin Expired - Lifetime CA2032475C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP11608689 1989-05-11
JP116086/1989 1989-05-11

Publications (2)

Publication Number Publication Date
CA2032475A1 true CA2032475A1 (fr) 1990-11-12
CA2032475C CA2032475C (fr) 1997-12-30

Family

ID=14678366

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002032475A Expired - Lifetime CA2032475C (fr) 1989-05-11 1990-05-10 Preparations pharmaceutiques pour administration par voie orale permettant la liberation du medicament dans des endroits cibles de l'intestin

Country Status (8)

Country Link
EP (1) EP0425699B1 (fr)
JP (1) JP2967492B2 (fr)
AT (1) ATE109973T1 (fr)
CA (1) CA2032475C (fr)
DE (1) DE69011618T2 (fr)
DK (1) DK0425699T3 (fr)
ES (1) ES2062527T3 (fr)
WO (1) WO1990013286A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE217789T1 (de) * 1992-06-04 2002-06-15 Smithkline Beecham Corp Angenehm schmeckende pharmazeutische zusammensetzungen
PT621032E (pt) * 1993-04-23 2001-01-31 Novartis Ag Dispositivo de distribuicao de libertacao controlada de farmaco
US5447729A (en) * 1994-04-07 1995-09-05 Pharmavene, Inc. Multilamellar drug delivery systems
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
SG80553A1 (en) * 1995-07-20 2001-05-22 Tanabe Seiyaku Co Pharmaceutical preparation in form of coated capsule releasable at lower part of digestive tract
JP3185206B2 (ja) * 1995-07-20 2001-07-09 田辺製薬株式会社 消化管下部放出型被覆カプセル製剤
JPH10152431A (ja) * 1996-08-02 1998-06-09 Hisamitsu Pharmaceut Co Inc 経口製剤用カプセルと経口カプセル製剤
IL128043A (en) * 1997-05-30 2004-08-31 Osmotica Corp Multi-layered osmotic device for controlled delivery of active agents
AU4800999A (en) 1998-07-28 2000-02-21 Tanabe Seiyaku Co., Ltd. Preparation capable of releasing drug at target site in intestine
JP2003201256A (ja) * 2001-12-28 2003-07-18 Hisamitsu Pharmaceut Co Inc 大腸送達性経口医薬製剤、大腸癌治療用経口医薬製剤および大腸炎治療用経口医薬製剤
JP4694145B2 (ja) * 2004-05-17 2011-06-08 株式会社 メドレックス 経口腸溶性製剤
US20060280795A1 (en) * 2005-06-08 2006-12-14 Dexcel Pharma Technologies, Ltd. Specific time-delayed burst profile delivery system
JPWO2008117814A1 (ja) 2007-03-26 2010-07-15 帝國製薬株式会社 大腸送達用経口製剤
JP2014529630A (ja) * 2011-09-07 2014-11-13 ザウラー−ブロシュ、ローラント 哺乳類の消化管における一つあるいは複数の物質の放出制御製剤
RU2744270C2 (ru) * 2015-12-28 2021-03-04 ЭсЭсПи КО., ЛТД., ДЖАПАН Прессованный фармацевтический препарат
WO2023068289A1 (fr) * 2021-10-20 2023-04-27 三生医薬株式会社 Composition pharmaceutique, et procédé de fabrication de celle-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2471186A1 (fr) * 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
DE3812799A1 (de) * 1988-04-16 1989-10-26 Sanol Arznei Schwarz Gmbh Oral zu verabreichende pharmazeutische zubereitung mit kontrollierter wirkstofffreisetzung und verfahren zu deren herstellung
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon

Also Published As

Publication number Publication date
ATE109973T1 (de) 1994-09-15
DE69011618T2 (de) 1994-12-15
DE69011618D1 (de) 1994-09-22
JP2967492B2 (ja) 1999-10-25
JPH0372417A (ja) 1991-03-27
EP0425699A4 (en) 1991-11-13
DK0425699T3 (da) 1994-11-21
WO1990013286A1 (fr) 1990-11-15
CA2032475C (fr) 1997-12-30
ES2062527T3 (es) 1994-12-16
EP0425699A1 (fr) 1991-05-08
EP0425699B1 (fr) 1994-08-17

Similar Documents

Publication Publication Date Title
CA2389235A1 (fr) Formulations d'hydrocodone a liberation lente
CA2326517A1 (fr) Nouvelles formes galeniques de meloxicame a administrer par voie orale
EG19642A (en) A process for the preparation of oral composition for the treatment of inflammatory bowel diseases
IE871584L (en) Sustained release capsule.
CA2230314A1 (fr) Formulations pharmaceutiques contenant de la darifenacine
IE871981L (en) Programmed release formulation.
CA2307018A1 (fr) Systeme osmotique de liberation de medicament
CA2034096A1 (fr) Formulation de naproxene a liberation controlee pour administration une fois par jour
IL106253A0 (en) Controlled release oral solid pharmaceutical dosage form and its preparation
CA2190148A1 (fr) Formulations d'alendronate liquide a absorption orale
MY100721A (en) Therapeutic agent.
CA2209714A1 (fr) Formulation a liberation controlee pour medicaments basiques peu solubles
DE58906926D1 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung.
EP0205282A2 (fr) Composition pharmaceutique pour la cavité buccale
WO1999007401A3 (fr) Utilisation de preparations d'erythropoietine et de fer pour la production de preparations pharmaceutiques mixtes destinees au traitement de maladies rhumatismales
CA2038744A1 (fr) Composition pharmaceutique contenant un medicament legerement hydrosoluble
CA2383212A1 (fr) Dosage oral a liberation regulee destine a l'administration orale
CA2313270A1 (fr) Utilisation de deferiprone pour le traitement et la prevention de maladies cardiaques induites par le fer
CA2180178A1 (fr) Utilisation des derives 2,3-diaryl-1-benzopyrane dans la production d'un medicament employe dans le traitement et la prevention de la diminution du volume du tissu osseux et de l'osteoporose
CHYATTE et al. The use of dantrolene sodium in disorders of the central nervous system
CA2091134A1 (fr) Agent therapeutique contre les risques d'avortement
Lund-Olesen et al. Intra-articular orgotein therapy in osteoarthritis of the knee. A double-blind, placebo-controlled trial
CA2361081A1 (fr) Traitement de la sclerose en plaques a la chaperonine 10 et au .beta.-interferon
WO1996030016A3 (fr) Formulations de ridogrel a petites doses et leur utilisation dans le traitement de maladies intestinales inflammatoires
Fodor et al. Review of three studies to determine the efficacy and tolerance of cicletanine in the short-and long-term treatment of essential hypertension

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry